181 related articles for article (PubMed ID: 23552834)
1. TRIPS-plus and access to medicines in China.
Chen J; Nie X; Yao P; Shi L
J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
[TBL] [Abstract][Full Text] [Related]
2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
McGIVERN L
Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
[TBL] [Abstract][Full Text] [Related]
3. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
6. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
7. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
8. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC; Forman L; Lipkus N
Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
[TBL] [Abstract][Full Text] [Related]
9. The ethics of intellectual property rights in an era of globalization.
Shah AK; Warsh J; Kesselheim AS
J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
[TBL] [Abstract][Full Text] [Related]
10. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
11. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
Townsend B; Gleeson D; Lopert R
Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
[TBL] [Abstract][Full Text] [Related]
12. Managing the effect of TRIPS on availability of priority vaccines.
Milstien J; Kaddar M
Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
[TBL] [Abstract][Full Text] [Related]
13. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
Luo J; Kesselheim AS
AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
[TBL] [Abstract][Full Text] [Related]
14. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
Son KB; Lee TJ
Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
[TBL] [Abstract][Full Text] [Related]
15. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
16. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
[TBL] [Abstract][Full Text] [Related]
17. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
Weber A; Mills L
Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
[TBL] [Abstract][Full Text] [Related]
18. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
Diependaele L; Cockbain J; Sterckx S
Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
[TBL] [Abstract][Full Text] [Related]
19. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.
Okeniyi SO; Okereke M
Pharm Pat Anal; 2022 Sep; 11(5):131-133. PubMed ID: 36177777
[No Abstract] [Full Text] [Related]
[Next] [New Search]
